The authors hypothesized that patients with CAA-related ICH may have higher cortical florbetapir retention and an occipital predominance compared to patients with deep ICH. They hypothesized that the increased retention may provide high diagnostic value to identify those ICH patients with CAA. The study prospectively enrolled 33 patients with acute symptomatic ICH from a single center.
Methods
This case-control study prospectively enrolled patients with acute spontaneous symptomatic ICH and classified them into 2 groups: lobar ICH patients fulfilling the modified clinical-MRI Boston criteria for probable CAA 5, 6 ; and deep ICH, as a comparison group. Patients with preexisting cognitive impairment, as determined by a score of ≥3.4 on the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE), were excluded from the study. All patients had to have undergone 3T MRI with blood-sensitive sequences (i.e., T2*-weighted gradient-recalled echo), to allow for CAA classification according to the Boston diagnostic criteria, and based on the presence of strictly lobar CMB, a putative hemorrhagic small vessel disease marker. Patients underwent 3T MRI approximately 15 days post-ICH (median, interquartile range [IQR] 9-28 days). MRI scans were then used to classify patients and assess small vessel disease neuroimaging markers according to Standards for Reporting Vascular Changes on Neuroimaging recommendations, blinded to all other clinical or PET data.
To examine the burden and regional pattern of amyloid in the brain of these patients, the authors appropriately performed amyloid-PET imaging with 18 F-florbetapir at an average 39 days (IQR 21-93 days) post-ICH, using standard methodology. Data were processed using FSL (fmrib.ox.ac.uk/fsl) in 3D T1-weighted images. Probability maps were generated with the FMRIB Automated Segmentation Tool (FSL library tools) using appropriate standard thresholding, coregistration of CT scan space onto T1 space, transformation matrixes, and anatomic regions of interest (ROIs). Global cortical and regional standardized uptake value ratio (SUVr) of florbetapir, which allows quantification of amyloid burden in the brain, was analyzed for each patient and compared between the 2 groups using t tests.
Florbetapir mean cortical retention was compared in 15 patients with acute CAA-related lobar ICH (mean age 63.7 ± 12, 40% female) and 18 patients with acute hypertensionrelated deep ICH (mean age 63.1 ± 11, 27.8% female). The contralesional (i.e., ICH-free) hemispheres of all participants were blindly assessed by 2 independent raters (who showed excellent interrater agreement, κ = 1), categorizing the PET florbetapir images as either florbetapir-positive or florbetapirnegative. To assess the performance of florbetapir, the area under the curve (AUC) and sensitivity and specificity for global florbetapir were estimated.
For basic definition of the terms mentioned in the article, see the table.
Results
The main results were that cortical florbetapir-PET uptake was increased in patients with CAA-related ICH compared to those with deep ICH. The 2 ICH groups were similar in their vascular risk factor profile (compared using Student t tests or Mann-Whitney U tests for normally and non-normally distributed continuous variables and χ 2 tests for categorical variables) with the exception of hypertension and APOE genotype. Hypertension was more prevalent in the deep ICH group and the APOE e2 or APOE e4 genotype was more prevalent in the CAA-ICH cohort. These differences in clinical characteristics are expected, given that the majority of deep ICHs are driven by hypertension or associated with vascular risk factor pathologies, while APOE is implicated in vascular amyloid accumulation pathophysiology.
Global cortical florbetapir retention was higher in CAA-ICH patients compared to deep ICH patients (SUVr 1.27 ± 0.12 vs 1.12 ± 0.12, p = 0.001, Cohen d = 1.25). Similarly, in univariable regional ROI analysis, florbetapir retention was higher in all individual cortical regions of the CAA-ICH patients when compared to the deep ICH patients. Among patients with CAA, the highest SUVr was estimated in the occipital lobe (1.31 ± 0.16). Of note, the occipital/whole cortex ratio was not different between CAA-ICH vs deep ICH patients (1.03 ± 0.07 vs 1.02 ± 0.05, p = 0.656).
The AUC for distinguishing CAA-ICH and deep ICH was 0.811 (95% confidence interval [CI] 0.642-0.980). At the SUVr threshold of 1.18, the sensitivity to differentiate CAA-ICH and deep ICH was 0.733 (95% CI 0.475-0.893) and the specificity was 0.833 (95% CI 0.598-0.948). Of all CAA-ICH patients, 60% (95% CI 0.352-0.848) were florbetapirpositive, in comparison to only 11% (95% CI 0.034-0.256) in the deep ICH group, based on visual analysis.
Discussion
The authors explored florbetapir, a well-established amyloid radioligand commonly used in Alzheimer disease, and examined its presence and spatial distribution in acute CAA-ICH patients vs deep ICH patients. The study confirms recent findings that florbetapir binding is increased in patients with CAA-related lobar ICH compared to patients with hypertension-related deep ICH. 7 The authors appropriately conclude that the use of florbetapir-PET does not seem to increase sensitivity or specificity for CAA diagnosis, beyond the modified Boston criteria, 6 and therefore has limited diagnostic value in clinical practice. Key strengths of the study include the combination of MRI and PET in the first weeks after ICH to evaluate CAA and comprehensive data on sensitivity and specificity of florbetapir to evaluate this new tracer as a potential diagnostic tool for the in vivo identification of CAA.
The findings of this interesting and elegant study need to be considered in the context of potential limitations, some of which are inherent to amyloid-PET studies in the field, 8 while others are more related to the selected methodology. The main points relevant for interpretation include the following:
1. The selection of the study sample may have resulted in a potential selection bias, which potentially limits generalizability of the results. For example, the reported mean NIH Stroke Scale score and hematoma volumes are relatively low, suggesting a clinically mild ICH population. The mean age of this sample is also relatively low (63.7 years), compared to previously reported CAA cohorts (;70 years). 9 PET imaging is likely better tolerated in relatively young and mildly affected patients with ICH. These factors may limit the study's generalizability, and hence these results might only be applicable to selected clinically mild ICH cases that do not represent the main bulk of patients seen in stroke clinics. In fact, florbetapir PET may be useful in quantifying amyloid burden in patients who present with both CAA and hypertensive small vessel disease pathology (i.e., mixed ICH/microbleeds cases in different combinations, a common diagnostic dilemma 8 )-these cases, as in previous studies, were not explicitly included as a separate well-defined group in the analysis. 3. The authors state in the Discussion that the current findings suggest that florbetapir binds vascular amyloid in CAA. However, this conclusion should be interpreted with caution, as it is not directly supported by the study design. Amyloid PET tracers that specifically bind vascular amyloid are not available yet, despite some promising recent developments. 8 Florbetapir PET, similar to other currently used amyloid tracers, is not specific for vascular amyloid, but instead binds both vascular and parenchymal amyloid, which often coexist in an older brain. It cannot be excluded that the different florbetapir retention values observed between the 2 groups might also be affected by factors beyond CAA, such as the coexistence of parenchymal amyloid, which is not entirely unlikely given the older age of the CAA-ICH group. The use of the IQCODE to exclude patients with pre-ICH cognitive impairment-such patients could have increased the chance of a false-positive findingmight not have been sufficient to overcome this issue. 4. The use of an additional control group (e.g., Alzheimer disease patients or young healthy controls) would have Cerebral amyloid angiopathy A chronic degenerative disease characterized by progressive deposition of β-amyloid in the media and adventitia of leptomeningeal vessels, small arteries, arterioles, and sometimes capillaries in the cerebral cortex. It commonly results in strictly lobar intracerebral hemorrhage and cerebral microbleeds in the elderly.
Cerebral microbleeds
Small (generally 2-5 mm in diameter, but sometimes up to 10 mm) areas of signal void with associated blooming seen on T2*-weighted MRI or other sequences that are sensitive to susceptibility effects. Results of some studies suggest that MRI-visible microbleeds correspond to hemosiderin-laden macrophages in perivascular tissue, consistent with vascular leakage of blood cells affected by small vessel disease.
Imaging analysis terms Segmentation
Dividing a scan (i.e., T1-weighted) into multiple anatomic structures of interest.
Gray matter probability map Maps where the intensity value of each voxel (i.e., 3D pixel) represents the probability that it belongs to gray matter.
Registration
Aligning an MRI sequence to another sequence using a transformation matrix, as to establish direct correspondence between their anatomical features.
PET
A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on a biologically active molecule. 3D images of tracer concentration within the body are then constructed by computer analysis. Receiver operating characteristic (ROC) An ROC curve plots true positive rate (sensitivity) and false-positive rate (100 − specificity) against each other. The closer the curve is to the upper left corner, the higher is the accuracy of the measure tested.
Area under the curve (AUC)
An AUC measures performance of a measure (how well measure can distinguish case/control or disease/normal). AUC can range from 0.5 (no better than chance) to 1 (perfect classification).
been interesting in disentangling the burden and patterns of florbetapir-PET. Beyond these limitations (many of them thoroughly discussed in the article), this work is important for the advancement of the field and will be useful in informing future studies on the diagnostic yield of amyloid-PET in CAA. Overall, the results point to the general consensus of the use of amyloid-PET in the setting of symptomatic CAA: a negative florbetapir-PET scan in a case with lobar or deep hemorrhages may rule out CAA as the underlying etiology, but a positive florbetapir-PET scan remains challenging to interpret, since the signal may come from vascular or parenchymal amyloid deposits. The interested reader is directed to a recent systematic review of amyloid-PET studies in CAA, including gaps and directions for future research in the field. critical revisions. Anand Viswanathan: critical revisions, supervision of the journal club and the report.
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